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A B S T R A C T
People with Down syndrome (DS) develop Alzheimer's disease (AD) at higher rates and a younger age of onset
compared to the general population. As the average lifespan of people with DS is increasing, AD is becoming an
important health concern in this group. Neuroimaging is becoming an increasingly useful tool in understanding
the pathogenesis of dementia development in relation to clinical symptoms. Furthermore, neuroimaging has the
potential to play a role in AD diagnosis and monitoring of therapeutics. This review describes major recent
ﬁndings from in vivo neuroimaging studies analysing DS and AD via ligand-based positron emission tomography
(PET), [18F] ﬂuorodeoxyglucose (FDG)-PET, structural magnetic resonance imaging (sMRI), and diﬀusion tensor
imaging (DTI). Electroencephalography (EEG) and retinal imaging are also discussed as emerging modalities.
The review is organized by neuroimaging method and assesses the relationship between cognitive decline and
neuroimaging changes. We ﬁnd that amyloid accumulation seen on PET occurs prior to dementia onset, possibly
as a precursor to the atrophy and white matter changes seen in MRI studies. Future PET studies relating tau
distribution to clinical symptoms will provide further insight into the role this protein plays in dementia de-
velopment. Brain activity changes demonstrated by EEG and metabolic changes seen via FDG-PET may also
follow predictable patterns that can help track dementia progression. Finally, newer approaches such as retinal
imaging will hopefully overcome some of the limitations of neuroimaging and allow for detection of dementia at
an earlier stage.
1. Introduction
Neuroimaging has important research and clinical implications in
people with Down syndrome (DS) and Alzheimer's disease (AD).
Correlating brain changes with clinical presentation can help uncover
the mechanisms of dementia development. Clinically, neuroimaging of
biomarkers can be used to track the development of AD in DS, allowing
for deep phenotyping and analysis of therapeutic eﬃcacy. Furthermore,
neuroimaging can be used along with clinical symptoms to help conﬁrm
a diagnosis of AD in people with DS. After discussing relevant back-
ground information regarding DS and AD, this review provides an
overview of clinical neuroimaging studies in the ﬁeld from the past
10 years. The review is organized by in vivo neuroimaging methods,
including ligand-based positron emission tomography (PET), [18F]
ﬂuorodeoxyglucose (FDG)-PET, structural magnetic resonance imaging
(sMRI), diﬀusion tensor imaging (DTI), electroencephalography (EEG),
and retinal imaging. Correlation of imaging changes to cognitive de-
cline is considered, and a discussion of the limitations and feasibility of
neuroimaging is included. This review is aimed at clinicians, psychol-
ogists, researchers, and those with an interest in DS and/or AD.
2. Background
2.1. Down syndrome overview
In order to appreciate the neuroimaging ﬁndings in people with DS
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and AD, it is important to understand the pathogenesis of DS and its link
to AD. DS is a genetic abnormality resulting from an extra copy of
chromosome 21, which manifests as intellectual disability and an array
of physical characteristics. The vast majority of cases are due to a
trisomy of chromosome 21, while 5% are due to Robertsonian
Translocation or mosaicism (Wilson et al., 2014). This results in an
increased dosage of the gene products on chromosome 21, which can
disrupt a variety of pathways, including those involved with brain de-
velopment, metabolism, and neuronal networks (Bouman and
Hennekam, 2015). In regards to epidemiology, DS is one of the most
common intellectual disabilities, occurring in 1/750 live births
(Antonarakis et al., 2004). The risk of having a child with DS is linked
to maternal age, with an 11/1000 chance in women over 40 (Puri and
Morris, 2015). As our understanding of DS has increased, the lifespan of
individuals with DS in developed countries has improved dramatically,
as the average person with DS now lives into their 50s (Zigman and
Lott, 2007). With this increase, it is important that we understand the
aging process in DS and provide appropriate support throughout the
lifespan.
2.2. Structural brain abnormalities in Down syndrome
Neurodevelopmental abnormalities in DS result in characteristic
brain features. People with DS are brachycephalic and have a reduced
overall brain size, with a speciﬁc reduction in the volume of the frontal
and temporal lobes and the cerebellum (Newton, 2015). Within the
temporal lobe, the superior temporal gyrus is reduced, while the
parahippocampal gyrus can be increased compared to the general po-
pulation. Recent ﬁndings (Lee et al., 2016) suggest that surface area
reductions rather than a decrease in cortical thickness are responsible
for the reduced cortical volume in certain areas. Furthermore, struc-
tural imaging ﬁndings (Annus et al., 2017) have found that the DS brain
has a thicker frontal and occipitoparietal cortex, a thinner motor cortex
and temporal pole, a smaller hippocampus and a larger putamen. Ad-
ditionally, people with DS tend to show accelerated aging in their
brains, demonstrating an adjusted brain-predicted age diﬀerence in-
crease of 7.69 years (Cole et al., 2017). It has been demonstrated
(Beacher et al., 2010) that the frontal, temporal and parietal lobes show
greater age-related reduction than the general population. Under-
standing these structural diﬀerences is important in order to have a
framework for how pathologies like dementia alter the DS brain.
2.3. Dementia and Down syndrome
AD is becoming an important health concern in people living longer
with DS. People with DS are at an increased risk of developing dementia
compared to the general population, and the onset occurs at a relatively
younger age (Wilson et al., 2014). The prevalence of dementia in people
with DS is about 3.4% in their 30s, 10.3% in their 40s, and 40% in those
over 50 (Holland et al., 1998). Dementia can be diﬃcult to diagnose in
this population for a number of reasons. Individuals with DS may have a
low baseline cognitive function, which can negatively aﬀect their per-
formance on cognitive tests designed for the general population that do
not take into account the pre-existing intellectual deﬁcits. People with
DS also vary considerably in their intellectual ability, and this hetero-
geneity makes it diﬃcult to establish reliable cut oﬀ scores on cognitive
tests. For these reasons, DS-speciﬁc neuropsychological tests that take
into account the spectrum of DS are needed in order to diagnose de-
mentia in this population. In addition to the need for specialized cog-
nitive tests, another challenge in diagnosis is that AD has a diﬀerent
initial presentation in DS compared to the general population, with
changes in personality and executive function often manifesting before
memory impairment (Wilson et al., 2014). One possible explanation for
this is that the frontal lobe in DS is underdeveloped and thus more
vulnerable to the eﬀects of amyloid (Holland et al., 2000), but further
research in this area is needed (Fonseca et al., 2016). An additional
issue in diagnosing AD in people with DS is that they may struggle with
communication, so there is often increased reliance on informant re-
ports for diagnosis. Finally, DS is often associated with sensory, neu-
rologic and psychiatric comorbidities which complicate the diagnosis of
AD (Newton et al., 2015). For all these reasons, neuroimaging may be
helpful as a complementary method of establishing a diagnosis and
monitoring AD in this population.
2.4. Pathogenesis: The amyloid cascade hypothesis and other potential
mechanisms
The amyloid cascade hypothesis is a major theory for the develop-
ment of AD. Amyloid beta (Aβ) is a product of one of the pathways of
amyloid precursor protein (APP) proteolysis, where APP is cleaved by
beta-secretase 1 and gamma-secretase (Querfurth and LaFerla, 2010).
Aβ peptides can vary slightly in length, and the Aβ42 form is particu-
larly prone to aggregation, arranging into beta sheets that are re-
sponsible for amyloid plaques (Yan and Wang, 2007). In addition to the
ﬁbrillar form, there are also oligomer forms of Aβ42 that may have an
even greater detrimental impact on neurons (Wilson et al., 2014). The
risk of AD is higher in people with DS compared to people with non-DS
intellectual disabilities (Strydom et al., 2013), and this is thought to be
due to the presence of APP on human chromosome 21 (Goldgaber et al.,
1987). The trisomy of chromosome 21 in people with DS therefore leads
to increased dosage of APP and accumulation of insoluble, neurotoxic
Aβ peptides.
Another biomarker for AD is tau, which correlates more closely with
cognitive decline (Wolfe, 2009). Tau is a protein that allows for axonal
transport of vesicles and organelles by associating with microtubules
(Wilson et al., 2014). In AD, tau can no longer associate with micro-
tubules because it is hyperphosphorylated and, as a result, neurotoxic
neuroﬁbrillary tangles (NFTs) are formed. Dual-speciﬁcity tyrosine-
phosphorylation-regulated kinase 1A is located on chromosome 21, and
excess of this kinase in DS could contribute to higher levels of hyper-
phosphorylated neurotoxic tau (Liu et al., 2008). On the other hand,
animal studies suggest that Aβ pathology drives tau pathology, pro-
viding support for the amyloid cascade hypothesis as the key me-
chanism of AD in DS (Götz et al., 2001). On a molecular level, some
ﬁndings suggest that amyloid inﬂuences the hyperphosphorylation of
tau, promoting the presence of this neurotoxic form (De Felice et al.,
2008). Regardless of the principle mechanism of tau pathogenesis, tau
clearly plays a key role in neuronal degeneration.
An additional proposed mechanism in AD development is neuroin-
ﬂammation. Amyloid plaques cause recruitment of microglia and in-
teract with receptors on these cells, leading to production of pro-in-
ﬂammatory cytokines and reactive oxygen species that are thought to
be neurotoxic (Zotova et al., 2010). Because this is a downstream eﬀect
of amyloid, involvement of neuroinﬂammation is consistent with the
amyloid cascade hypothesis of AD in DS. However, there is evidence of
people with DS showing increased baseline expression of IL-1, an in-
ﬂammatory cytokine, and chromosome 21 gene product S100B, a
protein that is elevated in reactive astrocytes (Wilcock and Griﬃn,
2013). This suggests that neuroinﬂammation may also be working in
parallel with the amyloid cascade to increase predisposition to AD.
In addition to these major theories, there are other genes on chro-
mosome 21 that could play a role in premature brain aging, such as
SOD-1 and SLC5A3 (Beacher et al., 2010). Mitochondrial dysfunction in
neurons and astrocytes could also be involved, either independently or
via altered metabolism of APP (Busciglio et al., 2002; Tiano and
Busciglio, 2011). In sum, there are likely several mechanisms hap-
pening simultaneously to contribute to AD development in people with
DS, but the amyloid cascade hypothesis is the most widely accepted
theory for this population. While not all with DS eventually develop AD,
these genetic factors certainly place them at risk.
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3. Methodology
To ensure that no other reviews exist on this exact topic, a thorough
search of Cochrane Library was performed. This review summarizes
recent ﬁndings from our lab as well as literature on neuroimaging in DS
and AD from the past 10 years. To identify articles about neuroimaging
in Down syndrome and dementia, a literature search on PUBMED was
performed using the keywords Alzheimer's disease OR dementia AND
MRI AND Down syndrome with the limiters of English, full text, and
published in the past 10 years. A MEDLINE search was then performed
using the keywords in a diﬀerent order (Down syndrome AND
Alzheimer's disease OR dementia AND MRI) with the same limiters. The
same steps were taken with the keywords Alzheimer's disease OR de-
mentia AND PET AND Down syndrome. Finally, an additional search
was made in this way using “neuroimaging” instead of “PET.” Sources
were also gained from the references of the selected literature.
Additionally, the books “Intellectual Disability and Dementia,” edited
by Karen Watchman, and “Down Syndrome: Current Perspectives,”
edited by Richard W Newton, Shiela Puri and Liz Marder, were used to
gather relevant background information and sources. Articles were
chosen for studies that involved DS subjects to assess in vivo neuroi-
maging changes and their relationship with cognitive decline and de-
mentia status.
4. Results: Neuroimaging trends in Down syndrome with
dementia
In this section, we present our ﬁndings from our literature review of
major neuroimaging studies in the ﬁeld from the past 10 years. We also
discuss studies using emerging modalities such as EEG and retinal
imaging.
4.1. PET
We review recent ﬁndings using in vivo PET to assess amyloid ac-
cumulation in people with DS (Table 1). We also include a discussion of
the current amyloid ligands available, and the potential for ligand-
based tau studies using PET in this population.
4.1.1. Amyloid ligands
In order to appreciate PET ligand-based ﬁndings, it is important to
include a discussion of the current amyloid ligands available. Pittsburgh
compound B (PiB) is used to assess amyloid accumulation in AD. PiB
speciﬁcally binds to amyloid arranged in beta sheets in classic plaques,
cerebrovascular amyloid angiopathy, and, to a lesser extent, diﬀuse
plaques (Cohen et al., 2012; LeVine et al., 2017; Lockhart et al., 2007).
One limitation of PiB is that it must be manufactured on-site due to its
short half-life, and thus ﬂuoride-based compounds can be a useful al-
ternative (Cohen et al., 2012; Sabbagh et al., 2011). While the current
amyloid ligands available are useful tools for detecting AD, one draw-
back is their limited ability to detect non-neuritic amyloid plaques that
may occur in a prodromal or early stage of dementia (Cairns et al.,
2009; Ikonomovic et al., 2008; Iwatsubo et al., 1995; Lemere et al.,
1996). Even among those with late-stage AD, there may be some PiB-
refractory cases due to molecular variants of Aβ (Rosen et al., 2010).
Thus, it is important to consider these caveats when interpreting in vivo
PET results.
4.1.2. Amyloid distribution based on PET
It has been known for several decades that Aβ accumulation is
nearly universal in people with DS over age 40, as demonstrated by
post-mortem studies (Mann et al., 1984). More recent methods have
used PET to visualize Aβ plaques in vivo with radioligands, and this
method has been shown to be safe and ethical in people with DS (Landt
et al., 2011). While even those with DS without clinical symptoms of
AD show amyloid binding, some of these studies demonstrate that
binding is increased with clinically diagnosed dementia status (Annus
et al., 2016; Sabbagh et al., 2015). Findings regarding the relationship
between amyloid binding and cognitive performance, however, have
been inconsistent (Annus et al., 2016; Cole et al., 2017; Hartley et al.,
2014; Nelson et al., 2011; Raﬁi et al., 2015). Nonetheless, regardless of
cognitive decline or dementia status, it has been consistently demon-
strated in PET studies that amyloid increases with age in this population
(Annus et al., 2016; Hartley et al., 2014; Jennings et al., 2015; Lao
et al., 2016, 2017; Nelson et al., 2011; Raﬁi et al., 2015; Sabbagh et al.,
2015). While causal relationships cannot be determined from these
ﬁndings, this predisposition of Aβ accumulation prior to dementia onset
is consistent with the amyloid cascade hypothesis.
The progression of amyloid accumulation seems to be unique in DS
individuals compared to sporadic AD. Recent studies have demon-
strated that the ﬁrst area of accumulation is the striatum (Annus et al.,
2016; Handen et al., 2012; Lao et al., 2016, 2017). Annus et al. (2016)
found that amyloid accumulation began in the striatum, starting around
age 40, followed by the rostral prefrontal-cingulo-parietal regions, then
caudal frontal, rostral temporal, primary sensorimotor and occipital
regions, and lastly the mediotemporal regions and remainder of the
basal ganglia. This may contrast with amyloid accumulation patterns in
sporadic AD in the general population, where an early striatal-only
phase has not been demonstrated (Thal et al., 2002). On the other hand,
early striatal binding is seen in familial autosomal dominant AD (Klunk
et al., 2007), leading Annus et al. (2016) to hypothesize that this early
stage may be unique to amyloid overproduction. Further research on
the signiﬁcance of early striatal binding may help elucidate the me-
chanism of dementia development in DS individuals.
In sum, PET ﬁndings analysing amyloid suggest that amyloid ac-
cumulation, beginning in the striatum, is a precursor to the develop-
ment of dementia. While those with dementia show increased levels of
amyloid, there is no clear association between amount of amyloid and
performance on cognitive tests. This suggests that while amyloid ac-
cumulation may be a necessary step in the progression to dementia,
there are likely downstream mechanisms more directly inﬂuencing
cognitive decline.
4.1.3. Tau distribution based on PET
Tau is a microtubule-associated protein that becomes hyperpho-
sphorylated in AD, leading to the formation of NFTs (Bouman and
Hennekam, 2015). In the general population, tau pathology is a more
accurate marker for cognitive decline in AD than amyloid pathology
(Brier et al., 2016). This relationship has been demonstrated in post-
mortem pathology of DS brains, correlating NFTs to cognitive decline
(Margallo-Lana et al., 2007). Certain markers like [18F]FDDNP PET
have been used to analyse both amyloid plaques and NFTs in this po-
pulation (Nelson et al., 2011), but there have not been any studies in
individuals with DS using PET to analyse tau distribution alone. Future
studies in this area may provide valuable insight into the relationship
between neuropathological changes and cognitive dysfunction in this
population. For example, AV1451 is a tracer increasingly being used to
study tau in AD that should prove useful (Golla et al., 2017). It is
possible that in vivo tau imaging will correlate more closely with
atrophy and cognitive measures compared to amyloid, providing a
missing link between amyloid overproduction and clinically detectable
dementia.
4.1.4. PET assessment of metabolic activity
FDG-PET is a useful neuroimaging tool in assessing neuronal ac-
tivity based on glucose metabolism. Changes in FDG have been shown
to be associated with cognitive function in people with DS (Haier et al.,
2008; Matthews et al., 2016; Raﬁi et al., 2015). Interestingly, even non-
demented DS individuals can demonstrate hypometabolism of the
posterior cingulate-precuneus, a region that is also hypometabolic in
AD in the general population (Matthews et al., 2016; Minoshima et al.,
1997). It has also been demonstrated that those with DS and AD have
N. Neale et al. NeuroImage: Clinical 17 (2018) 263–271
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reduced activity in the posterior cingulate relative to individuals with
DS but not AD (Sabbagh et al., 2015). While the relationship between
amyloid accumulation and these metabolic changes is not fully under-
stood, a small pilot study found an inverse relationship between amy-
loid accumulation and glucose metabolism (Raﬁi et al., 2015). On the
other hand, one study (Haier et al., 2008) found that some DS partici-
pants without clinical signs of dementia demonstrated a higher cerebral
glucose metabolic rate in areas of decreased grey matter volume
(temporal cortex, hippocampus, thalamus, caudate, and frontal lobe),
and that this combination of brain changes in these areas correlated to
dementia indicator ratings. It is possible that at an early stage dementia
development, metabolic activity is increased in these regions as a
compensatory mechanism, similar to some studies in early sporadic AD
showing increased metabolism in certain regions (Bookheimer et al.,
2000). Interestingly, the neuronal metabolite proﬁle is also diﬀerent in
DS with dementia relative to DS alone, providing further support that
metabolic changes are associated with the development of dementia in
this population (Lin et al., 2016). Thus, FDG PET and metabolite ana-
lysis may serve as useful detection tools for dementia. Future studies
analysing the chronologic relationship between metabolic changes and
cognitive performance would provide important insight on the devel-
opment of clinical dementia in DS.
4.2. MRI
In this section, we review recent MRI-based ﬁndings regarding AD
in DS (Table 2). We discuss studies that used sMRI to assess atrophy and
studies that used DTI to analyse white matter damage.
4.2.1. Structural MRI
Structural MRI imaging has elucidated the speciﬁc brain regions
impacted by dementia in DS. These grey matter changes can be de-
tectable before signs of clinical dementia (Matthews et al., 2016; Raﬁi
et al., 2015). Nonetheless, grey matter volume reductions seen by sMRI
likely occur after amyloid accumulation, as non-demented PiB positive
subjects with DS do not always show signs of atrophy (Lao et al., 2017).
Individuals with DS and AD eventually show decreased volume of the
hippocampus, amygdala, caudate, posterior cingulate, parietal, tem-
poral, frontal regions and putamen, as well as increased cerebrospinal
ﬂuid (Beacher et al., 2009; Sabbagh et al., 2015). It was recently de-
monstrated that those with DS and amyloid binding show posterior-
dominant cortical thinning and atrophy of hippocampus, thalamus, and
striatum, which is similar to what is seen in AD in the general popu-
lation (Annus et al., 2017). Thus, atrophy seems to be dependent on the
presence of amyloid and is exacerbated in those with dementia, con-
sistent with the theory that amyloid may drive atrophy and disease
progression.
4.2.2. Diﬀusion tensor imaging for white matter analysis
DTI is an MRI based method to assess the white matter of the brain.
Studies have found that those with DS have reduced white matter in-
tegrity, especially in the frontal tracts, and that decreased white matter
integrity correlates with cognitive dysfunction (Fenoll et al., 2017;
Powell et al., 2014). People with DS and dementia have been shown to
have decreased white matter integrity compared to non-demented DS
subjects (Powell et al., 2014). Another study found increased white
matter damage in PiB positive subjects with DS, but this eﬀect was seen
predominantly in the posterior tracts (Wilson, 2016). This is similar to
white matter dysfunction patterns seen in AD in the general population
(Medina and Gaviria, 2008). Interestingly, another recent study (Fenoll
et al., 2017) using DTI suggested that white matter degeneration was
not accelerated in non-demented DS subjects relative to normal aging
controls. Fenoll et al. suggests this ﬁnding could be due to limited
sensitivity of DTI in the pre-dementia stage or because accelerated
white matter damage may not occur until a later stage in dementia. Due
to the limited number of studies and conﬂicting results, further research
using DTI is necessary to determine the relationship between white
matter changes and AD in people with DS. It is possible that amyloid
accumulation exacerbates white matter damage in an already vulner-
able DS brain, but future studies are necessary to explain how this
happens mechanistically and relates to clinical symptoms.
4.3. Electroencephalogram (EEG)
Although not as widely used as PET or MRI, EEG is another potential
method of assessing AD in people with DS (Table 3). Even non-de-
mented adults with DS show decreased amplitude of alpha waves,
which is similar to what is seen in AD (Babiloni et al., 2010). Fur-
thermore, adults with DS and dementia show decreased frequency of
theta-1 waves compared to those with DS who do not have dementia
(Salem et al., 2015). Salem et al. also found that theta-1 frequency was
negatively correlated with scores on a dementia screening ques-
tionnaire, suggesting that increased brain wave abnormality may serve
as a marker of dementia progression. Additionally, dementia in DS can
be associated with senile myoclonic epilepsy, in which EEG changes
may follow a predictable pattern, beginning with diﬀuse abnormalities
during sleep at dementia onset followed by increased risk of myoclonic
epilepsy and ﬁnally non-epileptic myoclonus as the dementia pro-
gresses (d'Orsi and Specchio, 2014). Future EEG studies in this popu-
lation may complement other neuroimaging methods in understanding
and tracking dementia.
4.4. Retinal imaging
Another emerging neuroimaging approach to studying dementia
development is retinal imaging via optical coherence tomography
(OCT). As the optic nerve shares an embryonic origin with the brain and
is part of the central nervous system, the eye is susceptible to the same
neurodegenerative pathology such as amyloid plaques. In people with
AD in the general population, OCT has shown decreased retinal thick-
ness, and decreased macular volume is correlated with cognitive de-
cline (Iseri et al., 2006). It has also been demonstrated that Aβ accu-
mulation occurs in the lenses of people with DS (Moncaster et al.,
2010), as well as the retina (Raﬁi et al., 2015). Similar to PET amyloid
studies, it is unclear if there is a direct association between retina
amyloid accumulation and cognitive decline in DS (Raﬁi et al., 2015).
Nonetheless, this method is less invasive than MRI and PET, and has the
potential to detect AD at an earlier stage (Berisha et al., 2007).
5. Limitations & feasibility of neuroimaging
Neuroimaging has several limitations and thus should be used in
conjunction with cognitive and clinical assessments, as well as other
biological measures like plasma amyloid. One issue with neuroimaging
is that changes may not be detectable until the disease has progressed
signiﬁcantly. For example, radioligands such as PiB and ﬂorbetapir may
not be able to adequately detect diﬀuse Aβ plaques that occur early on
in the disease process, potentially limiting their usefulness as prodromal
biomarkers. Another issue is that the DS brain has signiﬁcant diﬀer-
ences from typical brains, which is important to keep in mind when
considering neuroimaging data. In order to distinguish brain changes
due to dementia from anomalies associated with DS, longitudinal stu-
dies are needed. Furthermore, it is diﬃcult to assess trends via meta-
analysis on neuroimaging results, as the studies are heterogeneous with
respect to imaging method, study design, and cognitive performance
measure. Finally, neuroimaging is costlier and more time-consuming
than other clinical tests, such as psychiatric assessments or plasma
amyloid analysis, limiting its feasibility as a widespread diagnostic tool.
Nonetheless, the relationship between neuroimaging changes and cog-
nitive function can be highly informative, especially as technology in
this ﬁeld improves.
It is also important to note certain limitations with respect to the
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studies considered. Many of these studies, particularly those using PET,
did not have participants with DS who also had a diagnosis of AD,
which limits the conclusions that can be drawn between neuroimaging
ﬁndings and dementia. This could also suggest a feasibility issue, so it is
important to consider the practicality of using neuroimaging in this
population for research and clinical purposes. Both low IQ and de-
mentia status have been associated with motion artefacts, and this is
particularly important for DTI and functional scans (Wilson, 2016).
None of the studies discussed used anxiolytics to address this issue,
despite the fact that they are sometimes used in the general population
prior to scans. There is controversy over the ethicality of using sedatives
in the DS population for this purpose, and additionally, these drugs can
aﬀect the results obtained from functional scans. The authors of this
review therefore recommend establishing a strong relationship with
participants and their caregivers and allowing participants the oppor-
tunity to familiarise with the process of scanning in order to achieve the
best outcomes.
6. Conclusions
Despite certain limitations, these recent neuroimaging ﬁndings can
help us begin to understand the mechanism of dementia in individuals
with DS. Aβ quantiﬁcation and distribution analysis using PET has re-
vealed a distinct pattern of amyloid accumulation, which may suggest
something unique about the pathogenesis of dementia in DS. This ac-
cumulation occurs in non-demented individuals with DS and is likely a
precursor to the grey matter atrophy and white matter integrity loss
seen in later stages of AD. From a clinical perspective, these discoveries
can potentially aid our screening and diagnosis of dementia in DS in-
dividuals. Monitoring these sequential changes, in conjunction with
neurocognitive tests and other biomarkers, may contribute to a more
comprehensive clinical picture and allow clinicians to more accurately
track dementia progression in this population.
Neuroimaging ﬁndings will also have important implications in
regards to therapeutics. For example, one implication of this research is
the identiﬁcation of a “therapeutic window” where clinicians can in-
tervene in high risk patients prior to disease progression. As changes
detected on certain neuroimaging methods such as ligand-based PET
and MRI may occur too late for eﬀective intervention, alternative
methods such as retinal imaging, EEG, and FDG-PET may prove parti-
cularly useful for this purpose. Early abnormalities detected via these
modalities could provide an opportunity to administer potential treat-
ments before the disease manifests clinically. In addition to identifying
a therapeutic window, neuroimaging can help inform novel therapeutic
targets. This is an area where research is greatly needed, as there are
currently no preventative treatments for AD. AD drugs to-date are
limited in eﬃcacy and are aimed at treating symptoms rather than the
underlying neurodegeneration (Castro et al., 2016). Finally, another
potential application of neuroimaging is to objectively monitor the ef-
ﬁcacy of future therapeutics. For all these reasons, neuroimaging and
other modalities discussed will likely have a valuable impact on our
treatment of AD.
While the clinical utility of this ﬁeld is evident, there are several
areas that require future research. For example, elucidating the re-
levance of early striatal accumulation to cognitive decline could inform
new cognitive screening measures (Sabbagh and Edgin, 2015). Ad-
ditionally, as tau correlates more strongly with cognitive decline than
Aβ (Brier et al., 2016), future studies with PET using tau ligand may
provide important insight. Tau ligands that have been applied in the
general population, such as AV1451 (Johnson et al., 2015), are starting
to be utilized for the DS population. Understanding how speciﬁc cog-
nitive deﬁcits are related to patterns of tau accumulation may help
explain the pathogenesis underlying the unique presentation of de-
mentia in DS. Furthermore, since there has not been a clear association
between amyloid distribution and atrophy, it will be useful to de-
termine if tau distribution follows the same pattern as brain atrophy
and serves as a link between the two processes. Another important area
of future research is the use of neuroimaging to analyse additional
markers of AD, such as glial cell markers, in people with DS (Wilcock
and Griﬃn, 2013). Finally, future DTI studies may help clarify the
impact of amyloid and tau accumulation on the white matter of the DS
brain, for example in the striatum. In general, high powered studies that
take a prospective longitudinal approach will be critical in increasing
our understanding of these mechanisms and identifying biomarkers for
tracking dementia development in DS (Caraci et al., 2017). This re-
search will ultimately have great signiﬁcance for the quality of life of
the increasing number of individuals with DS living into their 50′s and
beyond, and well as for AD prevention in the general population.
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